Intracavitary voriconazole for the treatment of hemoptysis complicating Pseudallescheria angusta pulmonary mycetomas in fibrocystic sarcoidosis.
Pulmonary mycetomas often occur in fibrocystic sarcoidosis. When this condition is complicated by hemoptysis, definitive surgery is usually precluded because of poor lung function. Intracavitary antifungal therapy has been described for the treatment of symptomatic pulmonary mycetomas. We report the first use of intracavitary voriconazole in the management of a Pseudallescheria angusta pulmonary mycetoma complicated by hemoptysis in a patient with fibrocystic sarcoidosis and renal transplant.
Kravitz
Jared N
JN
Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston, South Carolina 29425, USA.
Steed
Lisa L
LL
Judson
Marc A
MA
D000368:Aged; D000935:Antifungal Agents / Q000008:administration & dosage*; D006469:Hemoptysis / Q000175:diagnosis* / Q000188:drug therapy / Q000382:microbiology; D006801:Humans; D016867:Immunocompromised Host; D016030:Kidney Transplantation; D008172:Lung Diseases, Fungal / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy / Q000382:microbiology; D008297:Male; D008271:Mycetoma / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy / Q000382:microbiology; D011541:Pseudallescheria / Q000302:isolation & purification*; D011743:Pyrimidines / Q000008:administration & dosage*; D012507:Sarcoidosis / Q000150:complications*; D014230:Triazoles / Q000008:administration & dosage*; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole